MedPath

Comparison of two drugs for awake airway intubation in anaesthesia

Phase 4
Completed
Conditions
Patients posted for Surgery under General Anaesthesia
Registration Number
CTRI/2018/02/011696
Lead Sponsor
University College of Medical Sciences
Brief Summary

Study title : Comparison of fentanyl and nalbuphine on intubating conditions and haemodynamic responses during awake fiberoptic intubation

Rationale: Fiberoptic intubation is useful technique to secure airway in patients who have a difficult airway in terms of mouth opening and where conventional laryngoscopy is not possible .Opioids like fentanyl are commonly used to assist in the procedure .Recently,nalbuphine has used in conventional laryngoscopy and was found to be promising with minimal side effects .

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
62
Inclusion Criteria

Patients belonging to American society of Anaesthesiology grade I and grade II Patients belonging to MPG-I and MPG-II and Weight 40to 80 kg.

Exclusion Criteria

Patient refusal Patient with known allergy to trial drugs ASA-III and ASA-IV patients MPG-III and MPG-IV patients Emergency and obstetric surgeries Patients with respiratory disease Patient on beta blockers.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Level of sedation was evaluated by Ramsay sedation score0,5,10,15,20
Tolerance to intubation was evaluated by post intubation score0,5,10,15,20
Cough score0,5,10,15,20
Secondary Outcome Measures
NameTimeMethod
Heart rateSystolic Blood Pressure and Diastolic Blood Pressure

Trial Locations

Locations (1)

University College of Medical Sciences and Guru Teg Bahadur Hospital

🇮🇳

East, DELHI, India

University College of Medical Sciences and Guru Teg Bahadur Hospital
🇮🇳East, DELHI, India
Sachin Chaudhary
Principal investigator
8826140889
sachin.ucms@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.